Biologics Market Trends and Forecasts to 2027

Biologics Market Trends and Forecasts to 2027

  • November 2017 •
  • 300 pages •
  • Report ID: 5308396
Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn

Report Details
• Do you need definitive Biologics market data?
• Succinct Biologics market analysis?
• Technological insight?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.
Biologics form a vital part of the treatment portfolio for many serious chronic disorders, including cancer, diabetes, hepatitis and autoimmune diseases such as rheumatoid arthritis. This highly lucrative market is set to experience revenue growth to 2027, but will have to adapt to many new challenges along the way. Those challenges include patent expiries on many leading biological drugs, the emergence of biosimilars and cost-restricting measures in the face of limited national healthcare budgets.

Report highlights
• 155 quantitative tables, charts, and graphs across 300 pages
• Analysis of key Biologics in the Market
• Lantus
• NovoLog/NovoRapid
• Humalog
• Avonex
• Rebif
• Humira
• Remicade
• Tysabri
• Herceptin
• Kadcyla
• Perjeta
• Enbrel
• Eylea
• OsteoCel Plus
• Trinity Evolution and Trinity Elite
• Apligraf
• Dermagraft
• IMLYGIC

Global Biologics market outlook and analysis from to 2027

Global Biologics submarket forecasts and analysis from to 2027
• Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
• Vaccines

Regional Biologics market forecasts to 2027
• US forecast to 2027
• EU5 forecast to 2027
• Germany forecast to 2027
• UK forecast to 2027
• France forecast to 2027
• Italy forecast to 2027
• Spain forecast to 2027
• Japan forecast to 2027
• BRIC forecast to 2027
• Brazil forecast to 2027
• Russia forecast to 2027
• India forecast to 2027
• China forecast to 2027

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Biologics?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks